HYRB HyperBaric Systems Validates Platelet Preservation Technology
PALO ALTO, Calif.--(BUSINESS WIRE)--Nov. 15, 2001--HyperBaric Systems (OTCBB:HYRB - news) has achieved successful confirmation of its proprietary blood platelet preservation technology and is continuing its groundbreaking experiments at The Center for Blood Research in Sacramento.
Dr. David Lucas, Scientific Director for HyperBaric, had previously announced that experiments at its laboratory in Russia had demonstrated successful platelet function after ten days of cold storage.
``So far we have replicated our experiments in Sacramento for eight days and confirmed results achieved in Russia,'' he said. ``During the period when experiments in Sacramento were being conducted, we attained additional significant improvements in Russia that we want to implement as soon as possible.''
Dr. Lucas noted that, ``The majority of decay in platelets under refrigerated conditions takes place within the first 24 hours then becomes minimal thereafter. We have just recently discovered a significant enhancement to our cold-temperature technology that dramatically reduces the initial impact of cooling on the platelets. This is another very important achievement in the ongoing refinement of our platelet preservation technology.''
``We want to continue our experiments at The Center for Blood Research, implementing our new findings, and attain preservation periods exceeding ten days,'' Dr. Lucas stated.
``Our attention is now focused on these exciting new improvements and making arrangements with regulatory authorities to move forward with human infusion clinical studies.''
Before HyperBaric's breakthrough technology, experiments to store blood platelets in refrigerated conditions were attempted for more than forty years without success.
``In less than four years we have accomplished major achievements in the field of blood platelet preservation, what others have not done in the past forty years. This is just the beginning,'' Harry Masuda, HyperBaric President said.
``I believe our technology is going to save millions of dollars for blood banks, hospitals and medical centers. More importantly I believe we will save thousands of lives worldwide,'' he added.
Blood platelets, the congealing component of blood, are essential for use in patients undergoing chemotherapy treatments, organ transplants and major surgery.
``Currently, nearly half of the world's population has no access to blood platelets, primarily due to logistics created by their very limited shelf life,'' Bob Strom Vice President of Sales and Marketing said.
``Our extended preservation technology will allow the shipping of platelets to any global point and make inventory control a much easier task for the agencies involved.''
The new proprietary technology from HyperBaric Systems also helps solve the problem of bacterial damage to blood platelets by virtually halting all pathogen growth.
Bacterial growth during room temperature storage is considered to be one of the major dilemmas of platelet use.
``We don't create any additional costs in eliminating bacterial problems, because it is a natural result of our cold temperature technology,'' Dr. Lucas said.
HyperBaric Systems is headquartered in Palo Alto, California, with additional offices in the greater San Francisco Bay area and Rancho Mirage, California. The company also has research and testing facilities in Russia and Michigan.
Certain statements contained herein are ``forward-looking'' statements (as such term is defined in the Private Securities Litigation Reform Act of 1995). Because such statements include risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to the future results of research and development of the Company's products, the ability or inability to replicate test results, the ability to successfully commercialize the Company's products, and other risk factors discussed in filings made by the Company with the Securities and Exchange Commission.
--------------------------------------------------------------------------------
Contact:
HyperBaric Systems
Harry Masuda, 650/323-0943
E-mail: hmasuda@california.com
or
HyperBaric Systems
Bob Strom, 760/346-2698
E-mail: restrom3@cs.com
or
Yes International
Rich Kaiser, 800/631-8127
E-mail: rich@yesinternational.com
or
Wall Street Marketing
Mark Taggatz, 949/477-0640
E-mail: wsmg@earthlink.net
or
Intermark
Bobbi Cowan, 818/346-1975
E-mail: bcowanintermark@msn.com |
